4 Analysts Assess Ocugen: What You Need To Know

4 analysts have expressed a variety of opinions on Ocugen (NASDAQ:OCGN) over the past quarter, offering a diverse set of opinions from bullish to bearish.The table below summarizes their recent rating

Benzinga08:01 ET

Ocugen Completes Dosing of Second Group in Stargardt Eye Therapy Safety and Efficacy Study

Ocugen (OCGN) said Wednesday it has completed dosing of the second group of its phase 1/2 clinical study of its experimental gene modifier therapy candidate OCU41OST, being developed as a one-time tre

MT Newswires07:30 ET

Express News | HC Wainwright & Co. Reiterates Buy on Ocugen, Maintains $7 Price Target

Benzinga06:45 ET

Ocugen Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 316.67% HC Wainwright & Co. → $7 Reiterates Buy → Buy 04/22/2024 197.62% Chardan Capital $4 → $

Benzinga06:44 ET

Buy Rating Affirmed for Ocugen on Strong Financials and Advancing Clinical Pipeline

TipRanks06:36 ET

Express News | Ocugen Completed Dosing In The Second Cohort Of Its Phase 1/2 GARDian Clinical Trial For OCU410ST (AAV-HRORA), A Modifier Gene Therapy Candidate For Stargardt Disease As A One-time Treatment

Benzinga06:35 ET